Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophagesDa‐Liang Ou, Chiun Hsu|Journal for ImmunoTherapy of Cancer|2021Cited by 144
Alcoholism and Alcoholic Organ Damage and Genetic Polymorphisms of Alcohol Metabolizing Enzymes in Chinese PatientsYou‐Chen Chao, Chiun Hsu, Ton-Ho Young et al.|Hepatology|1997Cited by 124
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D’Alessio, David J. Pinato, Fionnuala Crowley et al.|The Lancet Oncology|2024Cited by 64
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 SuppressionChiun Hsu, Da‐Liang Ou|Clinical Cancer Research|2015Cited by 49